-
公开(公告)号：US08962018B2
公开(公告)日：2015-02-24
申请号：US12159030
申请日：2006-12-19
IPC分类号： A61K9/28 , A61K9/36 , A61K31/55 , A61K31/551
CPC分类号： A61K9/284 , A61K31/551
摘要： The invention relates to a solid formulation for the oral administration of olanzapine that comprises a core of anhydrous olanzapine Form I or a pharmaceutically acceptable salt thereof and, optionally, pharmaceutically acceptable excipients, said core being coated with a functional polymer that acts as filmogenic agent. The method for obtaining it comprises: i) providing anhydrous olanzapine Form I or a salt thereof and, optionally, pharmaceutically acceptable excipients in solid form; ii) providing a functional polymer that acts as filmogenic agent; iii) preparing a dispersion of said functional polymer in an aqueous medium,—and applying the dispersion obtained in step iii) onto the solid form of step i).
摘要翻译： 本发明涉及用于口服奥氮平的固体制剂，其包含无水奥氮平形式I或其药学上可接受的盐的核心，以及任选的药学上可接受的赋形剂，所述核心用作为成膜剂的功能性聚合物涂覆。 获得它的方法包括：i）提供无水奥氮平I型或其盐和任选的固体形式的药学上可接受的赋形剂; ii）提供充当成膜剂的功能聚合物; iii）将所述官能聚合物在水性介质中的分散体制备，并将步骤iii）中得到的分散体加到步骤i）的固体形式上。
-
公开(公告)号：US20090214646A1
公开(公告)日：2009-08-27
申请号：US12110555
申请日：2008-04-28
IPC分类号： A61K31/4365 , A61K9/28 , A61P7/02
CPC分类号： A61K9/2018 , A61K9/2013 , A61K9/2054 , A61K9/2059 , A61K31/4365
摘要： The present invention relates to a composition comprising a pharmaceutically acceptable salt of Clopidogel and isomalt as a diluent, to the use of said composition in the elaboration of an oral pharmaceutical formulation, as well as to an oral pharmaceutical formulation comprising said composition.
摘要翻译： 本发明涉及在制备口服药物制剂中使用所述组合物以及含有所述组合物的口服药物制剂的组合物，其包含氯吡格儿和异麦芽酮糖醇的药学上可接受的盐作为稀释剂。
-
3.发明申请公开(公告)号：US20080193527A1
公开(公告)日：2008-08-14
申请号：US11737462
申请日：2007-04-19
IPC分类号： A61K9/22 , A61K31/553
CPC分类号： A61K9/5015 , A61K9/1652 , A61K9/2018 , A61K9/2081
摘要： A granule formulation useful for preparation of pharmaceutical compositions. The granule formulation includes a core containing quetiapine or a pharmaceutically acceptable salt thereof as an active ingredient, and a binder agent. The core is coated with a coating layer including a lubricant agent. Solid pharmaceutical compositions containing quetiapine, and their preparation, are described.
摘要翻译： 用于制备药物组合物的颗粒制剂。 颗粒制剂包含含有喹硫平或其药学上可接受的盐作为活性成分的核心和粘合剂。 芯部涂覆有包含润滑剂的涂层。 描述了含有喹硫平的固体药物组合物及其制备方法。
-
公开(公告)号：US20090136571A1
公开(公告)日：2009-05-28
申请号：US12112808
申请日：2008-04-30
IPC分类号： A61K9/28 , A61K31/4184 , A61K31/546 , A61K9/00
CPC分类号： A61K31/415 , A61K9/2018 , A61K9/2077
摘要： The present invention relates to pharmaceutical compositions and formulations for the oral administration of Irbesartan, one of its pharmaceutically acceptable salts or its polymorphs, optionally combined with a diuretic and to a process for the manufacture of said composition.
摘要翻译： 本发明涉及用于口服给予厄贝沙坦的药物组合物和制剂，其为药学上可接受的盐或其多晶型物之一，任选地与利尿剂组合，以及制备所述组合物的方法。
-
公开(公告)号：US20080311203A1
公开(公告)日：2008-12-18
申请号：US12159030
申请日：2006-12-19
IPC分类号： A61K9/28 , A61K31/5513
CPC分类号： A61K9/284 , A61K31/551
摘要： The invention relates to a solid formulation for the oral administration of olanzapine that comprises a core of anhydrous olanzapine Form I or a pharmaceutically acceptable salt thereof and, optionally, pharmaceutically acceptable excipients, said core being coated with a functional polymer that acts as filmogenic agent. The method for obtaining it comprises: i) providing anhydrous olanzapine Form I or a salt thereof and, optionally, pharmaceutically acceptable excipients in solid form; ii) providing a functional polymer that acts as filmogenic agent; iii) preparing a dispersion of said functional polymer in an aqueous medium,—and applying the dispersion obtained in step iii) onto the solid form of step i).
摘要翻译： 本发明涉及用于口服奥氮平的固体制剂，其包含无水奥氮平形式I或其药学上可接受的盐的核心，以及任选的药学上可接受的赋形剂，所述核心用作为成膜剂的功能性聚合物涂覆。 获得它的方法包括：i）提供无水奥氮平I型或其盐和任选的固体形式的药学上可接受的赋形剂; ii）提供充当成膜剂的功能聚合物; iii）将所述官能聚合物在水性介质中的分散体制备，并将步骤iii）中得到的分散体加到步骤i）的固体形式上。
-
-
-
-
搜索结果
5 条记录 (耗时 0.015 秒)
